Retropubic,Laparoscopic,and Robot-Assisted Radical Prostatectomy: A Critical Review of Outcomes Reported by High-Volume Centers

Perioperative outcomes

The results for operative time, blood loss, blood transfusion rates, hospital stay, and overall complication rates for RARP, LRP, and RRP are presented on Table 1, ^{16 –36} , Table 2, ^{33,37 –47} and Table 3, ^{28,30,31,43,48 –54} respectively.

The weighted means for operative time were 165 minutes (range 131–204 min) for RRP, 162.6 minutes (130–236 min) for the RARP series, and 205 minutes (100–266 min) for the LRP series. The mean estimated blood loss (EBL) for RRP, LRP, and RARP was 951 mL, 291.5 mL, and 164.2 mL, respectively. The mean intraoperative and postoperative RRP transfusion rates for RRP, LRP, and RARP were 20.1%, 3.5%, and 1.4%, respectively.

In terms of hospital stay, RP series account for a weighted mean of 3.48 days; the mean hospital stay for LRP and RARP was 4.87 and 1.43 days, respectively.

The weighted mean postoperative complication rates for RRP, RLP, and RARP were 10.3% (range of means 4.8%–26.9%), 10.98% (range of means 8.9%–27.7%), and 10.3% (range of means 4.3%–15.7%), respectively.

Some RARP cases needed conversion to laparoscopy or RRP, and some of the RLP cases were converted to open surgery. The mean open conversion rate for RARP was 0.34% (range of means 0%–1.6 %) and for LRP was 1.76% (range of means 0%–2.4%).

Oncologic outcomes

The pathologic stage and PSM rates for open, RLP, and RARP series are summarized on Table 4, ^{16 –22,24 –28,30,31,33,55 –57} Table 5, ^{33,37,38,40 –42,44 –47} and Table 6, ^{30,31,35,48 –54,58} respectively.

The pathologic stage in the RARP series was of 78.2% pT₂ tumors and 20.5% pT₃ tumors. LRPs were performed on 64% pT₂ and 32.6% pT₃ tumors, and RRPs on 64.3% pT₂ and 31.5% pT₃ tumors. RARP revealed a mean overall PSM rate of 13.6%, whereas LRP and RRP yielded a PSM of 21.3% and 24%, respectively. The mean PSM rate for pT₂ and pT₃ tumors in the RARP series was 9.6% and 37.1%, respectively; in the open series, it was 16.8% and 42%, respectively; and in the LRP series, it was 12.4% and 39.2%, respectively.

Urinary continence outcomes

Postoperative urinary continence outcomes for RARP, LRP, and RRP are tabulated in Table 7, ^{16,17,23 –25,27,32 –35,59 –61} Table 8, ^{38,40 –42,44 –46,62} and Table 9. ^{35,48,50,51,53,58,63,64}

Direct comparisons for urinary continence rates between different prostatectomy series are difficult because of variations in definitions, data collection methods, and length of follow-up. In this review, the definition of continence that was adopted to collect the data from the studies was the use of no absorbent pads or the use of one pad only for security. We identified 14 RRP, 9 LRP, and 8 RARP studies with more than 250 patients and a follow-up longer than 6 months. The RRP continence rates ranged from 33.7% to 68%, 38.6% to 78%, 60.5% to 93.7%, and 58.1 to 96% at 3, 6, 12, and 18 months of follow-up, respectively. The LRP continence rates ranged from 51% to 76%, 70% to 95%, 82.3% to 95%, and 62.1 to 97% at 3, 6, 12, and 18 months of follow-up, respectively. Reports for RARP revealed continence rates of 47% to 93%, 61.9% to 97%, and 82.1% to 97% at 3, 6, and 12 months of follow-up, respectively. The weighted mean continence rates at 12 months of follow-up for RRP, LRP, and RARP were 79%, 84.8%, and 92%, respectively.

Potency outcomes

The potency rates for RRP, LRP, and RARP are detailed on Table 10 ^{17,23,24,32 –34,59,60,65 –68} Table 11, ^{33,38,40,41,44 –46,62,69} and Table 12. ^{35,48,51,53,63,64} As for continence, comparisons of the potency rates between different series are extremely difficult. Several ways to assess postoperative potency are used, including different questionnaires (International Index of Erectile Function, Expanded Prostate Cancer Index Composite) and distinct methods of data gathering (telephone, personal interviews, etc). The type of nerve-sparing procedure (unilateral, bilateral, nonnerve-sparing) and the use of medications can also influence the outcomes, in addition to the surgical approach adopted.

We identified 13 RRP, 9 LRP, and 6 RARP studies with more than 250 patients and with reported potency rates beyond 1 year. Evaluating RRP, the weighted mean potency rates for patients who underwent unilateral or bilateral nerve sparing, at 12 months of follow-up, were 43.1% and 60.6%, respectively. The LRP weighted mean potency rates for patients who received unilateral and bilateral nerve-sparing procedures, at 12 months of follow-up, were 31.1% and 54%, respectively; Finally, RARP patients who received unilateral and bilateral nerve-sparing procedures had potency rates, at 12 months of follow-up, of 59.9% and 93.5%, respectively.

Perioperative outcomes

It is difficult to compare operative times between different series because of variations in reporting operative time (including or not setup and/or pelvic lymph node dissection). In our study, the weighted mean operative times for RRP and RARP were similar (165 and 162.6 min, respectively). The weighted mean operative time (205 min) was longer in those patients who were undergoing LRP compared with the other two approaches. Similarly, the systematic review conducted recently by Ficarra and colleagues ¹³ suggested that RARP is more time consuming than RRP only in the earlier phase of the learning curve ⁷¹ but that such differences disappeared with increased surgical experience. The same meta-analysis also showed that the operative time is significantly longer in those patients who are undergoing LRP compared with RRP.

Badani and colleagues ⁴⁹ recently reported their experience after 2766 RARPs. For the entire cohort, the mean surgical time (calculated from the time of Veress needle placement to skin closure) and the mean console time was 154 minutes and 116 minutes, respectively. They compared the results of their first 200 patients (group 1) with their last 200 patients (group 2). For group 1, the mean surgical and console times were 160 minutes and 121 minutes, respectively; for group 2, the mean surgical and console times were 131 minutes and 97 minutes, respectively. The robotic setup and docking time also decreased from 45 minutes in group 1 to 8 minutes in group 2.

Decreased intraoperative blood loss has been reported to be a hallmark advantage of laparoscopic/robot-assisted prostatectomy. Because most intraoperative blood loss originates from the venous sinuses, the tamponade effect created by pneumoperitoneum helps to diminish blood loss. In addition, early identification and precise ligation of vessels facilitate the limitation of blood loss. In our study, the weighted mean EBL and the mean intraoperative and postoperative RRP transfusion rates were also higher for RRP than LRP and RARP (mean EBL 951 mL vs 291.5 mL vs 164.2 mL, respectively; transfusion rates 23%, 3.5%, and 1.4%, respectively). Two recent meta-analyses of studies that directly compared RRP, LRP, and RARP confirmed that RARP is associated with decreased operative blood loss and decreased risk of transfusion compared with RRP. ^13,14 It is noteworthy to mention, however, that some transfusion rates reported in RRP series are significantly biased by autologous blood transfusion protocols, which have a clearly more liberal indication for transfusion during the procedure. ³³

The mean in-hospital stay was higher for LRP series than in RRP and RARP in our review (4.87, 3.48, and 1.43 days, respectively). These results, however, probably reflected the differences in the location where the series were carried out. Most of the LRP series were conducted in Europe, where patients often stay in the hospital until the urinary catheter is removed; in the United States, the patients are usually discharged quickly from the hospital after surgery because of cultural disparities and differences in the insurance reimbursement patterns.

Surgical complications after RP have been documented in various previous series but few have used standardized classification systems. The absence of consensus within the surgical community on the best way to report complications has hampered accurate comparisons between different series and techniques. Lepor and coworkers, ¹⁹ for example, reported a 6.5% overall incidence of complications in a series of 1000 RRPs performed by a single surgeon. In their series, however, blood transfusion (9.7%) was not considered a complication. Most of the RARP series published include blood transfusion in their overall complication rates. Therefore, any direct comparison would be quite inaccurate.

Few studies that compare complications after large RRP, LRP, and RARP series are available in the literature. The results are conflicting. Hu and colleagues ⁴³ compared intraoperative and early postoperative complications of 358 consecutive LRPs with 322 RARPs and showed lower overall complication rates after RARP (27.7% vs 14.6%). Instead, Rozet and associates, ⁴⁰ in a matched-pair analysis of 133 extraperitoneal RARPs and 133 extraperitoneal pure LRP, demonstrated a higher overall complication rate after RARP (19.4% vs 9.1%, P = 0.01). Most available series that compare RRP and RARP have reported similar complication rates between these two approaches. Krambeck and coworkers ³⁵ recently showed comparable overall perioperative complication rates between RARP and RRP (8.0% vs 4.8%, P = 0.064). Similarly, Nelson and colleagues ²⁸ showed equivalent rates of unscheduled visits (RRP = 10%, RARP = 10%, P = 0.95) and readmissions (RRP = 5%, RARP = 7%, P = 0.12) because of postoperative complications between these two surgical approaches.

Ficarra and associates ¹³ showed in a cumulative analysis of comparative reports that the overall complication rate is significantly higher in those patients who are undergoing RRP. The same report showed that the complication rates after RARP or LRP are similar. In our review, the weighted mean postoperative complication rates were similar between the three approaches (10.3%, 10.98%, and 10.3%, respectively).

Oncologic outcomes

PSM after RP is thought to be an independent predictive factor of biochemical recurrence, local recurrence, and development of distant metastasis. ⁷² In the absence of long-term data that compare biochemical recurrence and disease-free survival between the different surgical approaches, data regarding PSM are most helpful as a surrogate for these outcomes. Few studies that compare PSM rates after RRP, LRP, and RARP are available, with conflicting results.

Parsons and Bennett ¹⁴ evaluated the surgical margin status in 13 comparative studies and showed no significant differences in overall risk or incidence of PSM between RRP and LRP or RARP. Of note, in the subgroup analysis by tumor stage, there were no significant differences between the groups for T₂ cancers or T₃ cancers. Likewise, Schroek and colleagues, ³⁰ comparing 362 consecutive RARPs with 435 RRPs, found no significant difference in PSM rates between RARP and RRP. The risk of PSA recurrence was also not significantly different after adjusting for clinical (hazard ratio 0.82, 95% confidence interval [CI] 0.48–1.38; P = 0.448) and pathologic differences (0.94, 0.55–1.61; P = 0.824). Similarly, Krambeck and coworkers ³⁵ showed, in their matched-pair analysis, no difference in the PSM rates between RARP and RRP. The 3-year biochemical disease-free survival was also not significantly different.

Contrary to these results, Ficarra and associates, ¹³ evaluating PSM rates in six studies that compared RARP and RRP, suggested a significant advantage in the population who underwent RARP (relative risk [RR]: 1.58; 95% CI of RR: 1.29–1.94; P < 0.00001). When analyzing the PSM rates in patients with organ-confined prostate cancer, RARP was associated with the lowest risk of PSMs (RR: 2.23; 95% CI of RR: 1.36–3.67; P = 0.002). The PSM rates observed after open RP and LRP were similar. Our analysis that included high-volume centers confirmed this trend to lower PSM rates after RARP compared with RRP and LRP, because this surgical approach revealed a weighted mean overall PSM rate of 13.6%, whereas LRP and RRP yielded a PSM rate of 21.3% and 24%, respectively. PSM rates for pT₂ tumors were also lowest among RARP series (16.8% for RRP; 12.4% for LRP, and 9.6% for RARP). Randomized trials are necessary, however, before establishing definitive conclusions.

Urinary continence outcomes

Objective evaluation of continence outcomes after RP remains stalled by the lack of standardization among series. Most studies used no validated institutional questionnaires, and the outcomes were assessed by an open interview.

Very few data regarding continence are available in the studies that compared RARP with LRP or with RRP, and meaningful conclusions as to whether any particular approach delivers superior continence outcomes are impractical. Nevertheless, better continence rates were suggested after RARP in some previous studies. Tewari and coworkers ⁷³ showed, in a nonrandomized comparative study, that RARP provides earlier continence recovery compared with RRP. These authors reported a prospective comparison between 100 RRPs and 200 RARPs and demonstrated a shorter time to return of continence after RARP (median time 160 vs 44 days; P < 0.05).

Contrarily to these results, Krambeck and associates ³⁵ in a matched comparison of RRP and RARP, showed comparable continence rates at the 1-year follow-up (RARP 91.8%, RRP 93.7%, P = 0.344). Likewise Parsons and Bennett ¹⁴ evaluated urinary continence at 1 year of follow-up in four comparative studies. There was no significant difference in urinary continence between LRP or RARP and RRP.

Ficarra and coworkers ¹³ analyzed eight articles that provided data on urinary continence recovery after RRP or LRP. Considering the studies that evaluated the learning curve of LRP, the return of continence was better after RRP. The cumulative analysis suggested similar continence rates after RRP or LRP, however. The cumulative analysis that compared RARP with RRP was not possible because of the heterogeneity of the studies. ¹³

In our review, the weighted mean continence rates at 12 months for RRP, LRP, and RARP were 80%, 84.8%, and 92%, respectively. Our data support the statement that the continence rates after RRP and LRP are similar. The RARP continence rates were higher in our study when compared with RRP and LRP. Randomized prospective studies are necessary, however, to accurately compare the continence rates between the three surgical approaches.

Potency outcomes

Potency is one of the most difficult outcomes to compare after RP. Factors other than the surgeon or the approach have a significant effect on recovery of potency, including patient age, type and quality of the nerve sparing, and use of medications. Also, the assessment of postoperative continence is not standardized, including nonvalidated questionnaires and open interviews.

Whether there is a difference in the potency rates after RRP, LRP, or RARP is still not clear. It has been proposed that RARP may prevent damage to the neurovascular bundle because the three-dimensional magnified vision offered by the Da Vinci Surgical System allows more precise dissection and prevents inadvertent incision, traction, or incorporation of the neurovascular bundle into the suture or clip. Tewari and colleagues ⁷³ demonstrated better and earlier potency recovery after RARP compared with RRP. Patients who underwent RARPs showed earlier return of erections (50% at a mean follow-up of 180 days vs 50% at a mean of 440 days after RRP) as well as a quicker return to intercourse (50% at 340 days vs 50% at 700 days for RRP) compared with RRP patients. Contrary to these results, the matched-pair analysis conducted by Krambeck and coworkers ³⁵ showed comparable potency rates between RARP and RRP at 1-year follow-up. (RARP 70.0%, RRP 62.8%, P = 0.081).

Regarding the comparison between RARP and LRP, Joseph and associates ⁷⁴ conducted a single retrospective study that compared noncontemporary series of patients who were evaluated for erectile function recovery after LRP and RARP. At 3 months after surgery, only a nonstatistically significant trend in favor of RARP was observed. In our review, the weighted mean potency rates for bilateral nerve sparing were higher for RARP compared with the other two surgical approaches (93% vs 60.6% for RRP vs 54% for LRP). The poor methodology of the published studies and the absence of randomized clinical trials prevent any definitive conclusions, however.

Our study has some limitations. Although we included only high-volume centers in our analysis, several centers have multiple surgeons who perform RARP and LRP. Therefore, the individual learning curve of each surgeon could have been a source of bias. In addition, the series analyzed in each group are not contemporary. The outcomes from the RRP series are based on less contemporary patient cohorts. Therefore, some of the patients in the open RRP series were operated on before widespread use of PSA screening; baseline patient characteristics were not consistently comparable—ie, the pathologic stage was more advanced in the RRP series compared with the RARP series. Finally, comparison of outcomes using weighted means has some inherent limitations; a single large series with suboptimal outcomes can determine a worse weighted mean even if excellent results are reported in several smaller series.